Literature DB >> 23934781

Identification of subgroups of schizophrenia patients with changes in either immune or growth factor and hormonal pathways.

Emanuel Schwarz1, Nico J M van Beveren2, Jordan Ramsey1, F Markus Leweke, Matthias Rothermundt3, Bernhard Bogerts4, Johann Steiner4, Paul C Guest1, Sabine Bahn5.   

Abstract

Schizophrenia is a heterogeneous disorder normally diagnosed using the Diagnostic and Statistical Manual of Mental Disorders criteria. However, these criteria do not necessarily reflect differences in underlying molecular abnormalities of the disorder. Here, we have used multiplexed immunoassay analyses to measure immune molecules, growth factors, and hormones important to schizophrenia in acutely ill antipsychotic-naive patients (n = 180) and matched controls (n = 398). We found that using the resulting molecular profiles, we were capable of separating schizophrenia patients into 2 significantly distinct subgroups with predominant molecular abnormalities in either immune molecules or growth factors and hormones. These molecular profiles were tested using an independent cohort, and this showed the same separation into 2 subgroups. This suggests that distinct abnormalities occur in specific molecular pathways in schizophrenia patients. This may be of relevance for intervention studies that specifically target particular molecular mechanisms and could be a first step to further define the complex schizophrenia syndrome based on molecular profiles.
© The Author 2013. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  diagnosis; growth factors; immune factors; molecular profiling; schizophrenia; subtypes

Mesh:

Substances:

Year:  2013        PMID: 23934781      PMCID: PMC4059436          DOI: 10.1093/schbul/sbt105

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  40 in total

1.  Inference of population structure using multilocus genotype data.

Authors:  J K Pritchard; M Stephens; P Donnelly
Journal:  Genetics       Date:  2000-06       Impact factor: 4.562

2.  Neuroscience. Deconstructing schizophrenia.

Authors:  Constance Holden
Journal:  Science       Date:  2003-01-17       Impact factor: 47.728

3.  The STARD initiative.

Authors:  Patrick M Bossuyt; Johannes B Reitsma
Journal:  Lancet       Date:  2003-01-04       Impact factor: 79.321

Review 4.  Multiple genes and factors associated with bipolar disorder converge on growth factor and stress activated kinase pathways controlling translation initiation: implications for oligodendrocyte viability.

Authors:  C J Carter
Journal:  Neurochem Int       Date:  2007-01-18       Impact factor: 3.921

5.  Serum prolactin levels in unmedicated schizophrenic patients.

Authors:  H Y Meltzer; E J Sachar; A G Frantz
Journal:  Arch Gen Psychiatry       Date:  1974-10

Review 6.  Heterogeneity of schizophrenia.

Authors:  M T Tsuang
Journal:  Biol Psychiatry       Date:  1975-08       Impact factor: 13.382

7.  Novel endocrine disrupter effects of classic and atypical antipsychotic agents and divalproex: induction of adrenal hyperandrogenism, reversible with metformin or rosiglitazone.

Authors:  Gül Bahtiyar; Karolina Weiss; Alan S Sacerdote
Journal:  Endocr Pract       Date:  2007-10       Impact factor: 3.443

8.  Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease.

Authors:  Tomohiko Sato; Haruo Hanyu; Kentaro Hirao; Hidekazu Kanetaka; Hirofumi Sakurai; Toshihiko Iwamoto
Journal:  Neurobiol Aging       Date:  2009-11-17       Impact factor: 4.673

9.  A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia.

Authors:  Yechiel Levkovitz; Shlomo Mendlovich; Sharon Riwkes; Yoram Braw; Hana Levkovitch-Verbin; Gilad Gal; Shmuel Fennig; Ilan Treves; Shmuel Kron
Journal:  J Clin Psychiatry       Date:  2009-11-03       Impact factor: 4.384

10.  Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia.

Authors:  Martina C M Ryan; Patrick Collins; Jogin H Thakore
Journal:  Am J Psychiatry       Date:  2003-02       Impact factor: 18.112

View more
  27 in total

Review 1.  Antineuronal antibodies against neurotransmitter receptors and synaptic proteins in schizophrenia: current knowledge and clinical implications.

Authors:  Johann Steiner; Kolja Schiltz; Hans-Gert Bernstein; Bernhard Bogerts
Journal:  CNS Drugs       Date:  2015-03       Impact factor: 5.749

Review 2.  Is there a role for immune-to-brain communication in schizophrenia?

Authors:  Golam M Khandaker; Robert Dantzer
Journal:  Psychopharmacology (Berl)       Date:  2015-06-04       Impact factor: 4.530

3.  Changes in BQCA Allosteric Modulation of [(3)H]NMS Binding to Human Cortex within Schizophrenia and by Divalent Cations.

Authors:  Brian Dean; Shaun Hopper; P Jeffrey Conn; Elizabeth Scarr
Journal:  Neuropsychopharmacology       Date:  2015-10-29       Impact factor: 7.853

Review 4.  Extracellular matrix proteomics in schizophrenia and Alzheimer's disease.

Authors:  Manveen K Sethi; Joseph Zaia
Journal:  Anal Bioanal Chem       Date:  2016-09-06       Impact factor: 4.142

5.  Comorbidity of schizophrenia and infection: a population-based cohort study.

Authors:  Philip Rising Nielsen; Thomas Munk Laursen; Esben Agerbo
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2016-10-19       Impact factor: 4.328

6.  Distinct Phenotypes of Inflammation Associated Macrophages and Microglia in the Prefrontal Cortex Schizophrenia Compared to Controls.

Authors:  Yunting Zhu; Maree J Webster; Caitlin E Murphy; Frank A Middleton; Paul T Massa; Chunyu Liu; Rujia Dai; Cyndi Shannon Weickert
Journal:  Front Neurosci       Date:  2022-06-30       Impact factor: 5.152

7.  Levels of Red Blood Cell Fatty Acids in Patients With Psychosis, Their Unaffected Siblings, and Healthy Controls.

Authors:  Suzanne Medema; Roel J T Mocking; Maarten W J Koeter; Frédéric M Vaz; Carin Meijer; Lieuwe de Haan; Nico J M van Beveren; René Kahn; Lieuwe de Haan; Jim van Os; Durk Wiersma; Richard Bruggeman; Wiepke Cahn; Carin Meijer; Inez Myin-Germeys
Journal:  Schizophr Bull       Date:  2015-09-18       Impact factor: 9.306

8.  Inflammatory molecular signature associated with infectious agents in psychosis.

Authors:  Lindsay N Hayes; Emily G Severance; Jeffrey T Leek; Kristin L Gressitt; Cathrin Rohleder; Jennifer M Coughlin; F Markus Leweke; Robert H Yolken; Akira Sawa
Journal:  Schizophr Bull       Date:  2014-04-17       Impact factor: 9.306

9.  Immuno-inflammatory changes across phases of early psychosis: The impact of antipsychotic medication and stage of illness.

Authors:  Skylar Kelsven; Camilo de la Fuente-Sandoval; Cristian L Achim; Francisco Reyes-Madrigal; Heline Mirzakhanian; Isabel Domingues; Kristin Cadenhead
Journal:  Schizophr Res       Date:  2020-02-20       Impact factor: 4.939

Review 10.  Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment.

Authors:  Golam M Khandaker; Lesley Cousins; Julia Deakin; Belinda R Lennox; Robert Yolken; Peter B Jones
Journal:  Lancet Psychiatry       Date:  2015-02-25       Impact factor: 27.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.